MiNK Therapeutics Says First Patients Treated With agenT-797 In Phase 2 Severe Hypoxemic Pneumonia Trial Alive At Day 28 With Improved Oxygenation, Infection Control

Loading news article.

MiNK Therapeutics Says First Patients Treated With agenT-797 In Phase 2 Severe Hypoxemic Pneumonia Trial Alive At Day 28 With Improved Oxygenation, Infection Control | WAPE

MiNK Therapeutics Says First Patients Treated With agenT-797 In Phase 2 Severe Hypoxemic Pneumonia Trial Alive At Day 28 With Improved Oxygenation, Infection Control

Article summary

Related companies

Comments —